This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BioTime Adds Five New Stem Cell Lines To Its Product Portfolio

BioTime, Inc. (AMEX:BTIM) announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime’s ACTCellerate™ technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells. The new lines will include W10 with markers of smooth muscle progenitors, RASMO12 with unique markers associated with the kidney, U31 with markers associated with the neurotransmitter dopamine useful in research in Parkinson’s disease and diseases of the autonomic nervous system, as well as the lines SK11, EN1, and 7SMOO7, properties of which will be disclosed on product launch. BioTime CEO Dr. Michael West will discuss these new products as part of a presentation today at the GTCbio 6th Annual Stem Cell Research & Therapeutics Conference in Boston, Massachusetts. These new cell lines may be purchased beginning June 1, 2010, and additional information about the products may be found, at http://www.embryome.com/products.htm.

Dr. West’s presentation at the GTCbio Conference will focus on stem cell differentiation and will describe BioTime’s recent efforts to generate highly purified, diverse, and scalable embryonic progenitor (EP) cell types for potential use in human cell therapy, including six cell types with potential use in orthopedic disease. A complete abstract of Dr. West’s presentation is available on the conference website at www.gtcbio.com, and a copy of the presentation will be available on BioTime’s website at www.biotimeinc.com.

The annual GTCbio Stem Cell Research & Therapeutics Conference provides leading-edge information on developments in all areas of stem cell research, including the biology, medicine, applications, regulations, and business of stem cells. This year's sessions will include discussions of the new federal funding opportunities that are arising as alternative sources of human embryonic stem cells emerge.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs